Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Am J Med. 2017 Aug;130(8):992-995. doi: 10.1016/j.amjmed.2017.03.054. Epub 2017 Apr 29.

Giant-Cell Arteritis: Do We Treat Patients with Large-Vessel Involvement Differently?

Author information

1
Department of Internal Medicine, Caen University Hospital, University of Caen-Basse Normandie, France. Electronic address: deboysson-h@chu-caen.fr.
2
Department of Internal Medicine, Limoges University Hospital, France.
3
Department of Internal Medicine, Lille University Hospital, France.
4
Department of Internal Medicine, Caen University Hospital, University of Caen-Basse Normandie, France.
5
Department of Nuclear Medicine, Caen University Hospital, France; Normandy University, Caen, France.

Abstract

PURPOSE:

We aimed to describe the initial treatment that was used in a common hospital-based practice in patients with giant-cell arteritis with and without large-vessel involvement at diagnosis as well as the outcomes in both groups.

METHODS:

This retrospective multi-center cohort included patients with giant-cell arteritis diagnosed between 2005 and 2015, all of whom had fluorodeoxyglucose (FDG) positron emission tomography combined with computed tomography (FDG-PET/CT) performed at giant-cell arteritis diagnosis and were followed up for ≥12 months. We compared the features, treatment, and outcomes of patients with large-vessel involvement demonstrated on FDG-PET/CT with those of patients with a negative PET/CT.

RESULTS:

Eighty patients (50 women, median age: 71 [53-87] years) were included, 40 of whom had large-vessel involvement demonstrated on FDG-PET/CT and 40 who did not. After a median 56-month follow-up time, 42 (53%) patients had discontinued glucocorticoid (GC) treatment. Patients with and without large-vessel involvement were indistinguishable in the initial median dose of prednisone (0.74 mg/kg vs 0.75 mg/kg, P = .56), overall GC duration (P = .77), GC discontinuation rate (P = .65), relapse rate (P = .50), frequency of GC-dependent disease requiring GC-sparing treatments (P = .62), and fatality rate (P = .06).

CONCLUSION:

In the setting of tertiary hospital recruitment, large-vessel involvement at giant-cell arteritis diagnosis using a PET/CT study had no influence on the choice of initial GC dose and had no impact on outcomes. Prospective studies are required to confirm these findings.

KEYWORDS:

Aortitis; FDG-PET/CT; Giant-cell arteritis; Large-vessel vasculitis; Treatment

PMID:
28460851
DOI:
10.1016/j.amjmed.2017.03.054
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center